Myeloma News and Research

RSS

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

Managing Myeloma (www.ManagingMyeloma.com), an accredited educational website for multidisciplinary professionals, has launched a forum designed specifically for oncology nurses. The goal of the nursing forum is to share insight about day-to-day practice challenges in caring for patients with multiple myeloma, provide updates on clinical advances, and connect with peers.

20 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

New study suggests possible genetic link between environmental toxins and myeloma

The International Myeloma Foundation (IMF) today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma. Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affect production of blood cells and can damage bone.

14 Aug 2009

Discovery of possible genetic link between environmental toxins and bone disease in multiple myeloma

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma.

13 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Thalidomide does not improve survival in small cell lung cancer

Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, according to a new study published online July 16 in the Journal of the National Cancer Institute.

17 Jul 2009

Vegetarians less likely to develop cancer than meat eaters

Vegetarians are 12 per cent less likely to develop cancer than meat eaters, according to new research published in the British Journal of Cancer.

1 Jul 2009

First report on cancer incidence and ethnicity

The National Cancer Intelligence Network (NCIN) and Cancer Research UK has today (Thursday) published the first report on cancer incidence and ethnicity.

24 Jun 2009

Certain pesticides double the risk of blood disorder

A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population.

13 Jun 2009

Formaldehyde exposure among industrial workers linked to greater risk of cancers of the blood and lymphatic system

Results from an ongoing study of workers employed at plants that used or produced formaldehyde continue to show a possible link between formaldehyde exposure and death from cancers of the blood and lymphatic system, particularly myeloid leukemia.

12 May 2009

X-rays help predict permanent bone damage from bisphosphonates

Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates. These drugs have been found to place people at risk for developing osteonecrosis of the jaws (a rotting of the jaw bones).

7 May 2009

Cancer rates among U.S. elderly, minorities set to explode

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45 percent, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly and minority populations, according to research from The University of Texas M. D. Anderson Cancer Center.

29 Apr 2009

Study predicts dramatic growth in cancer rates among US elderly, minorities

29 Apr 2009

Protein FGFR3 a potential therapeutic target for several cancers

Several forms of cancer, including bladder cancer and multiple myeloma caused by the t(4;14) genetic abnormality, are associated with either overexpression or perpetual activation of the protein FGFR3.

20 Apr 2009

Discovery of gene that protects against leukemia

Researchers have identified a gene that controls the rapid production and differentiation of the stem cells that produce all blood cell types -- a discovery that could eventually open the door to more streamlined treatments for leukemia and other blood cancers, in which blood cells proliferate out of control.

9 Apr 2009

Novel hemodialysis procedure improves health of cancer patients

A novel hemodialysis procedure helps restore kidney function and increases lifespan in patients with multiple myeloma, according to a study appearing in the April 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN).

1 Apr 2009

Discovery of new cancer gene

Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes.

29 Mar 2009

Small molecules block cancer gene

Finding molecules that block the activity of the oncogene Stat 3 (signal transducer and activator of transcription) required screening literally millions of compounds, using computers that compared the structure of the cancer-causing gene to those of the small molecules, said a Baylor College of Medicine researcher in a report that appears in the current online issue of the journal PLoS One (Public Library of Science ONE).

11 Mar 2009

Proepithelin encourages cell growth and migration in prostate cancer

Researchers from Thomas Jefferson University have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells.

26 Feb 2009